Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02159807 · ClinicalTrials.gov registry record · NA
Optimizing Dose of Bupivacaine in Combined Spinal Epidurals To Reduce Side Effects
A NA study, sponsored by St. Luke's-Roosevelt Hospital Center.
- Completed
- Registry status
- NA
- Development phase
- 170
- Enrollment target
NCT02159807: Completed NA study, sponsored by St. Luke's-Roosevelt Hospital Center.
NCT02159807 is a NA study that has completed, run by St. Luke's-Roosevelt Hospital Center. The registered enrollment target is 170 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02159807, a NA study, has completed, sponsored by St. Luke's-Roosevelt Hospital Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 170 participants
- Enrollment target
Study Summary
The purpose of this study is to determine what dose of medication administered through a combined spinal epidural (CSE) provides the optimal pain relief with the minimal amount of side effects. The 3 doses studied here (1.25, 1.66 and 2.5mg) are routinely use on the labor floor (depending on the physician preference) but the idea is to quantify safety, efficacy and side effects for each of these doses.
Primary Outcome
Maternal diastolic blood pressure at 60 minutes after epidural to measure maternal hypotension
Interventions
- DRUG Bupivacaine
- DRUG Fentanyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2015-04-24 |
| Est. Completion | 2017-12-29 |
| Phase | NA |
What the finished NCT02159807 record still lists
NCT02159807 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.
NCT02159807 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02159807 about?
NCT02159807 is a clinical study titled "Optimizing Dose of Bupivacaine in Combined Spinal Epidurals To Reduce Side Effects". The purpose of this study is to determine what dose of medication administered through a combined spinal epidural (CSE) provides the optimal pain relief with the minimal amount of side effects. The 3 doses studied here (1.25, 1.66 and 2.5mg) are routinely use on the labor floor (depending on the phy...
What is the current status of trial NCT02159807?
This trial is currently completed. It is a NA study. The enrollment target is 170 participants. The study started on 2015-04-24. Estimated completion is 2017-12-29.
What interventions are being tested in trial NCT02159807?
The interventions under investigation include: Bupivacaine (DRUG), Fentanyl (DRUG).
Who is sponsoring clinical trial NCT02159807?
This trial is sponsored by St. Luke's-Roosevelt Hospital Center, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02159807's enrollment target sits among peer trials
170 614th of 2000 higher than 1,382 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI